Studies indicated that the piroxicam ceramic nanoparticle formulations elicited release of piroxicam in 1 h 15 min. This result also indicated specific interaction Hippo pathway inhibitor of piroxicam and trehalose. In the absence of sugar adsorption, the piroxicam release was to the tune of 90% in 60 min., which can be usefully exploited for the immediate action.”
“Osteoporosis

is an escalating global problem. Hip fractures, the most catastrophic complication of osteoporosis, continue to cause significant mortality and morbidity despite increasing availability of effective preventative agents. Among these agents, oral bisphosphonates have been the first choice for the treatment and prevention of osteoporotic fractures. However, the use of oral bisphosphonates, especially in the older population, has been limited by their AZD6244 in vivo side effects and method of administration thus compromising their persistent use. The resultant low adherence by patients has undermined their full potential and has been associated with an increase in the incidence of fragility fractures. Recently, annual intravenous zoledronic acid (ZOL) has been approved for osteoporosis.

Randomized controlled trials have demonstrated ZOL to be safe, have good tolerability and produce significant effect on bone mass and micro-architecture. Adherence has also been shown to be better with ZOL. Furthermore two large trials firmly demonstrated significant anti-osteoporotic effect (similar to 59% relative risk reduction of hip fractures) and mortality benefit (28% reduction in mortality)

of ZOL in older persons with recent hip fractures. In click here this review, we report the current evidence on the use of ZOL for the prevention of hip fractures in the elderly. We also report the pharmacological characteristics and the advantages and disadvantages of ZOL in this particular group.”
“Objective To determine clinical signs and outcomes of methylphenidate hydrochloride (MPH) toxicosis in dogs; to assess effects of amount lie, dose) and formulation (immediate or extended release) of ingested MPH on onset, duration, and severity of clinical signs; and to describe management of MPH intoxication.

Design Retrospective case series.

Animals-128 dogs with MPH toxicosis or exposure.

Procedures Data from an Animal Poison Control Center (APCC) database from November 1, 2001, to November 30, 2008, were reviewed. Records of dogs were searched for APCC classifications of confirmed (n = 71) or suspected (39) MPH toxicosis; dogs (18) that ingested MPH but did not develop clinical signs of toxicosis were also included. Signalment, dose, clinical signs, treatment, and outcome were evaluated.

Results Clinical signs of toxicosis were reported in 107 of 128 (84%) dogs that ingested MPH; these included hyperactivity in 42 (33%), tachycardia in 27 (21%), vomiting in 19 (15%), agitation in 16 (13%), and hyperthermia in 13 (10%). Doses ranged from 0.36 mg/kg (0.164 mg/lb) to 1170 mg/kg (53.18 mg/lb).